Dyana T.Saenz, PhD, Christopher Peter Mill, PhD BA, Warren Fiskus, BSc, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD
Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivnt in Patients with Desmoid Tumors.
Motonari Nomura, Nino Rainusso, Yi-Chien Lee, Brian Dawson, Cristian Coarfa, Ruolan Han, Jeffrey L Larson, Ryan Shuck, Lyazat Kurenbekova, Jason T Yustein.
Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN.
Iterion Therapeutics, formerly known as Beta Cat Pharmaceuticals, today announced that it has initiated a multi-center Phase 1 clinical study of Tegavivint, its lead therapeutic candidate, in patients with desmoid tumors that are unresectable and symptomatic or progressive.
Savvidou I, Khong T, Cuddihy A, McLean C, Horrigan S, Spencer A.
Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S.
Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN.
